Search Results - "Cuppens, Kristof"

Is Intravenous and Oral Topotecan in Small-Cell Lung Cancer Truly Equal? A Case Report by Deraedt, Davien, Verfaillie, Saartje, Wynants, Jokke, Cuppens, Kristof

“…Treatment with topotecan is standard-of-care therapy for relapsed small-cell lung cancer (SCLC). Both oral and intravenous administrations of topotecan have…”
Get full text

Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications by Vandekerckhove, Olivia, Cuppens, Kristof, Pat, Karin, Du Pont, Bert, Froyen, Guy, Maes, Brigitte

“…Lung cancer remains the leading cause of cancer death worldwide, with the majority of cases diagnosed in an advanced stage. Early-stage disease non-small cell…”
Get full text

Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient by Caeyman, Aaron, Vandekerckhove, Olivia, Pat, Karin, Wynants, Jokke, Weytjens, Karolien, De Wergifosse, Isabelle, Cuppens, Kristof

“…Abstract In this report, we present a patient with metastatic non-small cell lung cancer who developed Sjögren’s syndrome secondary to immune checkpoint…”
Get full text

Triple Trouble: A Case of Multiple Resistance Mechanisms after First Generation EGFR-TKI in NSCLC by Ralki, Mike, Maes, Brigitte, Pat, Karin, Wynants, Jokke, Cuppens, Kristof

“…Epidermal growth factor receptor (EGFR)-targeted therapy has become standard of care in advanced stages EGFR-mutant non-small cell lung cancer. Acquired…”
Get full text

Idiopathic pleuroparenchymatous fibroelastosis: A case report and brief review of the literature by Cuppens, Kristof, Verbeken, Eric, Coolen, Johan, Verschakelen, Johny, Wuyts, Wim

“…Abstract We describe a patient with idiopathic pleuroparenchymal fibroelastosis (IPPFE). This rare clinicopathological syndrome is characterized by typical…”
Get full text

The path forward in early-stage lung cancer by Cuppens, Kristof, Baas, Paul

Get full text

Vaccination therapy for non-small-cell lung cancer by Cuppens, Kristof, Vansteenkiste, Johan

“…PURPOSE OF REVIEWRecent advances in our understanding of cancer immunology resulted in the development of promising therapeutic agents for either…”
Get full text

HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors by Cuppens, Kristof, Baas, Paul, Geerdens, Ellen, Cruys, Bert, Froyen, Guy, Decoster, Lynn, Thomeer, Michiel, Maes, Brigitte

“…•High HLA-I diversity and high TMB, alone or in combination, is associated with favorable clinical outcomes to PD-1 inhibiting immunotherapy.•HLA-I diversity…”
Get full text

Immune checkpoint inhibition in early-stage non-small cell lung cancer by Cuppens, Kristof, Du Pont, Bert, Knegjens, Joost, Maes, Brigitte, Baas, Paul

“…•Immune checkpoint inhibition is a cornerstone of the multimodality surgical treatment of early-stage NSCLC.•Neoadjuvant immune checkpoint inhibitor and…”
Get full text

UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN) by Bar, Jair, Peled, Nir, Schokrpur, Shiruyeh, Wolner, Mirjana, Rotem, Ofer, Girard, Nicolas, Aboubakar Nana, Frank, Derijcke, Sofie, Kian, Waleed, Patel, Sandip, Gantz-Sorotsky, Hadas, Zer, Alona, Moskovitz, Mor, Metro, Giulio, Rottenberg, Yakir, Calles, Antonio, Hochmair, Maximilian, Cuppens, Kristof, Decoster, Lynn, Reck, Martin, Limon, Dror, Rodriguez, Estelamari, Astaras, Christoforos, Bettini, Adrienne, Häfliger, Simon, Addeo, Alfredo

“…Approximately 10% of EGFR mutations (EGFRmuts) are uncommon (ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with ucEGFRmuts…”
Get more information

The Adenosinergic Pathway in Non-Small Cell Lung Cancer by Van Kerkhove, Olivier, Verfaillie, Saartje, Maes, Brigitte, Cuppens, Kristof

“…Immune checkpoint inhibitors (ICIs) targeting PD-(L)1 and CTLA-4 have revolutionized the systemic treatment of non-small cell lung cancer (NSCLC), achieving…”
Get full text

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial by Schuler, Martin, Cuppens, Kristof, Plönes, Till, Wiesweg, Marcel, Du Pont, Bert, Hegedus, Balazs, Köster, Johannes, Mairinger, Fabian, Darwiche, Kaid, Paschen, Annette, Maes, Brigitte, Vanbockrijck, Michel, Lähnemann, David, Zhao, Fang, Hautzel, Hubertus, Theegarten, Dirk, Hartemink, Koen, Reis, Henning, Baas, Paul, Schramm, Alexander, Aigner, Clemens

“…Antibodies targeting the immune checkpoint molecules PD-1, PD-L1 and CTLA-4, administered alone or in combination with chemotherapy, are the standard of care…”
Get full text

Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung by Aigner, Clemens, Du Pont, Bert, Hartemink, Koen, Wiesweg, Marcel, Vanbockrijck, Michel, Darwiche, Kaid, Hegedus, Balazs, Schramm, Alexander, Hautzel, Hubertus, Maes, Brigitte, Theegarten, Dirk, Schildhaus, Hans-Ulrich, Baas, Paul, Cuppens, Kristof, Schuler, Martin H., Plönes, Till

“…8500 Background: Feasibility of surgical resection for non-small-cell lung cancer (NSCLC) after preoperative immune checkpoint inhibitor therapy (PICIT) with…”
Get full text

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib by Awada, Ahmad, Berghmans, Thierry, Clement, Paul M., Cuppens, Kristof, De Wilde, Bram, Machiels, Jean-Pascal, Pauwels, Patrick, Peeters, Marc, Rottey, Sylvie, Van Cutsem, Eric

“…[Display omitted] •NTRK fusions are the primary oncogenic driver of a broad range of adult and pediatric cancers.•Though rare, NTRK fusions represent an…”
Get full text

Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial by Cho, Byoung Chul, Lee, Jong Seok, Wu, Yi-Long, Cicin, Irfan, Dols, Manuel Cobo, Ahn, Myung-Ju, Cuppens, Kristof, Veillon, Rémi, Nadal, Ernest, Dias, Josiane Mourão, Martin, Claudio, Reck, Martin, Garon, Edward B, Felip, Enriqueta, Paz-Ares, Luis, Mornex, Francoise, Vokes, Everett E, Adjei, Alex A, Robinson, Clifford, Sato, Masashi, Vugmeyster, Yulia, Machl, Andreas, Audhuy, Francois, Chaudhary, Surendra, Barlesi, Fabrice

“…Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β "trap") fused to a human immunoglobulin…”
Get more information

A rare cause of recurrent hemopneumothorax by Ralki, Mike, Yilmaz, Alaaddin, Vanwing, Jacques, Cuppens, Kristof

“…: Angiosarcoma is a rare and aggressive tumor of vascular endothelial origin. Pulmonary metastasis can lead to potential life-threatening complications, such…”
Get full text

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial by Camidge, D Ross, Bar, Jair, Horinouchi, Hidehito, Goldman, Jonathan, Moiseenko, Fedor, Filippova, Elena, Cicin, Irfan, Ciuleanu, Tudor, Daaboul, Nathalie, Liu, Chunling, Bradbury, Penelope, Moskovitz, Mor, Katgi, Nuran, Tomasini, Pascale, Zer, Alona, Girard, Nicolas, Cuppens, Kristof, Han, Ji-Youn, Wu, Shang-Yin, Baijal, Shobhit, Mansfield, Aaron S, Kuo, Chih-Hsi, Nishino, Kazumi, Lee, Se-Hoon, Planchard, David, Baik, Christina, Li, Martha, Ansell, Peter, Xia, Summer, Bolotin, Ellen, Looman, Jim, Ratajczak, Christine, Lu, Shun

“…Telisotuzumab vedotin (Teliso-V) is a c-Met-directed antibody-drug conjugate with a monomethyl auristatin E cytotoxic payload. The phase II LUMINOSITY trial…”
Get full text

Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanisms by Bar, Jair, Peled, Nir, Schokrpur, Shiruyeh, Dudnik, Elizabeth, Wollner, Mira, Girard, Nicolas, Aboubakar Nana, Frank, Derijcke, Sofie, Kian, Waleed, Patel, Sandip P., Gantz Sorotsky, Hadas Yocheved, Zer, Alona, Moskovitz, Mor, Metro, Giulio, Rottenberg, Yakir, Calles, Antonio, Hochmair, Maximilian, Cuppens, Kristof, Decoster, Lynn, Addeo, Alfredo

“…9109 Background: About 10% of EGFR mutations (EGFRm) are ‘uncommon mutations’ (ucEGFRm). osimertinib is a 3 rd generation EGFRi, active against common EGFRm…”
Get full text

Characteristics and outcome of unplanned hospital admissions in patients with lung cancer: a longitudinal tertiary center study. Towards a strategy to reduce the burden by Cuppens, Kristof, Oyen, Christel, Derweduwen, Aurélie, Ottevaere, Anouck, Sermeus, Walter, Vansteenkiste, Johan

“…Background Unplanned hospital admissions (UHAs) are frequent in lung cancer, but literature on this topic is scarce. The aim of this study is to gain insight…”
Get full text

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment by Agbarya, Abed, Shalata, Walid, Addeo, Alfredo, Charpidou, Andriani, Cuppens, Kristof, Brustugun, Odd Terje, Rajer, Mirjana, Jakopovic, Marco, Marinca, Mihai V, Pluzanski, Adam, Hiltermann, Jeroen, Araújo, António

“…Daily-practice challenges in oncology have been intensified by the approval of immune checkpoint inhibitors (ICI). We aimed to outline current therapy policies…”
Get full text